Trials / Terminated
TerminatedNCT04635527
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
A Phase Ib Study to Evaluate the Safety and Efficacy of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI318 | before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W |
| PROCEDURE | cTACE | conventional transarterial chemoembolization |
| DRUG | placebo | before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W |
Timeline
- Start date
- 2020-12-24
- Primary completion
- 2021-08-27
- Completion
- 2023-03-07
- First posted
- 2020-11-19
- Last updated
- 2023-03-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04635527. Inclusion in this directory is not an endorsement.